Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S0600: Irinotecan and Cetuximab with or without Bevacizumab in mCRC
NCT00499369Phase 3Terminated
- Sponsor
- National Cancer Institute
- Start
- Jun 2007
- Primary completion
- Nov 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in metastatic colorectal cancer (mCRC), sponsored by National Cancer Institute. Started Jun 2007; status: terminated.
02
Drugs
bevacizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00499369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00499369.